|Table of Contents|

Research progress in salvage treatment after failure of BCG for non-muscular invasive bladder cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 22
Page:
4272-4279
Research Field:
Publishing date:

Info

Title:
Research progress in salvage treatment after failure of BCG for non-muscular invasive bladder cancer
Author(s):
WANG Yinda; GENG Bo; LI Xuedong
Department of Urology,the Second Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150000,China.
Keywords:
non-muscle-invasive bladder cancer; intravesical therapy; BCG failure; salvage therapy
PACS:
R737.14
DOI:
10.3969/j.issn.1672-4992.2023.22.034
Abstract:
Transurethral resection of bladder tumor combined with postoperative adjuvant bladder perfusion BCG has become the standard first-line treatment for non-muscular invasive bladder tumor at present.But there are still some patients with disease recurrence or progression after BCG treatment.Although radical cystectomy is the standard-of-care for patients failing BCG therapy,some patients are unable or unwilling to undergo radical cystectomy after failure of BCG treatment.They need to take other salvage treatment.In this paper,we review the literature on salvage treatment after failure of BCG treatment and summarize the use and research status of relevant agents.In addition to the traditional intravesical chemotherapy,many new treatments have emerged,such as modified BCG,immune checkpoint inhibitors,chemotherapy hyperthermia,photodynamic therapy,viral gene therapy,targeted therapy,checkpoint inhibitors and so on.New treatments may bring more choices and better outcomes for patients in the future.

References:

［1］ STEINBERG RL,THOMAS LJ,O'DONNELL MA,et al.sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer ［J］.Bladder Cancer,2015,1(1):65-72.
［2］ BABJUK M,BOHLE A,BURGER M,et al.EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder:Update 2016 ［J］.Eur Urol,2017,71(3):447-461.
［3］ LENIS AT,LEC PM,CHAMIE K,et al.Bladder cancer:A review ［J］.Jama,2020,324(19):1980-1991.
［4］ CHANG SS,BOORJIAN SA,CHOU R,et al.Diagnosis and treatment of non-muscle invasive bladder cancer:AUA/SUO guideline ［J］.J Urol,2016,196(4):1021-1029.
［5］ LENDINEZ-CANO G,RIVERO-BELENCHON I,MEDINA-LOPEZ RA.Recurrence and progression after BCG［J］.Arch Esp Urol,2020,73(10):929-933.
［6］ SYLVESTER RJ,VAN DER MEIJDEN AP,WITJES JA,et al.Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder:a meta-analysis of the published results of randomized clinical trials ［J］.J Urol,2005,174(1):86-91,discussion-2.
［7］ RENTSCH CA,BOSSHARD P,MAYOR G,et al.Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC,a recombinant mycobacterium Bacillus Calmette Guérin (BCG),in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy ［J］.Oncoimmunology,2020,9(1):1748981.
［8］ MALMSTROM PU,WIJKSTROM H,LUNDHOLM C,et al.5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma.Swedish-Norwegian Bladder Cancer Study Group ［J］.J Urol,1999,161(4):1124-1127.
［9］ STEINBERG G,BAHNSON R,BROSMAN S,et al.Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder.The Valrubicin Study Group ［J］.J Urol,2000,163(3):761-767.
［10］ COOKSON MS,CHANG SS,LIHOU C,et al.Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer,including carcinoma in situ of the bladder ［J］.Ther Adv Urol,2014,6(5):181-191.
［11］ DALBAGNI G,BENFANTE N,SJOBERG DD,et al.Single arm phase I/II study of everolimus and intravesical gemcitabine in patients with primary or secondary carcinoma in situ of the bladder who failed Bacillus Calmette Guerin (NCT01259063) ［J］.Bladder Cancer,2017,3(2):113-119.
［12］ SKINNER EC,GOLDMAN B,SAKR WA,et al.SWOG S0353:Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin ［J］.J Urol,2013,190(4):1200-1204.
［13］ HURLE R,CONTIERI R,CASALE P,et al.Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure ［J］.Urol Oncol,2020,39(3):195.e7-195.e13.
［14］ BARLOW LJ,MCKIERNAN JM,BENSON MC.Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy ［J］.J Urol,2013,189(3):834-839.
［15］ GRADISHAR WJ,TJULANDIN S,DAVIDSON N,et al.Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer ［J］.J Clin Oncol,2005,23(31):7794-7803.
［16］ MCKIERNAN JM,HOLDER DD,GHANDOUR RA,et al.Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guérin treatment failure ［J］.J Urol,2014,192(6):1633-1638.
［17］ ROBINS DJ,SUI W,MATULAY JT,et al.Long-term survival outcomes with intravesical nanoparticle albumin-bound paclitaxel for recurrent non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin therapy ［J］.Urology,2017,103:149-153.
［18］ NAZMIFAR M,WILLIAMS C,NASER-TAVAKOLIAN A,et al.Clinical and preclinical therapies for bladder cancer following Bacillus Calmette-Guérin failure ［J］.The Journal of Urology,2023,209(1):32-48.
［19］ VASEKAR M,DEGRAFF D,JOSHI M.Immunotherapy in bladder cancer ［J］.Curr Mol Pharmacol,2016,9(3):242-251.
［20］ STEINBERG RL,NEPPLE KG,VELAER KN,et al.Quadruple immunotherapy of Bacillus Calmette-Guérin,interferon,interleukin-2,and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer ［J］.Urol Oncol,2017,35(12):670.e7-e14.
［21］ COCKERILL PA,KNOEDLER JJ,FRANK I,et al.Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer ［J］.BJU Int,2016,117(3):456-462.
［22］ DECASTRO GJ,SUI W,PAK JS,et al.A phase I trial of intravesical cabazitaxel,gemcitabine and cisplatin for the treatment of nonmuscle invasive bacillus Calmette-Guérin unresponsive or recurrent/relapsing urothelial carcinoma of the bladder ［J］.J Urol,2020,204(2):247-253.
［23］ CHEVURU PT,MCELREE IM,MOTT SL,et al.Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer ［J］.Urologic Oncology,2023,41(3):148.e1-e7.
［24］ PENTICUFF JC,WOOLBRIGHT BL,SIELECKI TM,et al.MIF family proteins in genitourinary cancer:tumorigenic roles and therapeutic potential ［J］.Nat Rev Urol,2019,16(5):318-328.
［25］ TAYLOR JA,KUCHEL GA,HEGDE P,et al.Null mutation for macrophage migration inhibitory factor (MIF) is associated with less aggressive bladder cancer in mice ［J］.BMC Cancer,2007,7:135.
［26］ CHOUDHARY S,HEGDE P,PRUITT JR,et al.Macrophage migratory inhibitory factor promotes bladder cancer progression via increasing proliferation and angiogenesis ［J］.Carcinogenesis,2013,34(12):2891-2899.
［27］ CHOUDHARY S,PRUITT JR,SIELECKI TM,et al.Abstract 159:Macrophage migration inhibitory factor (MIF) enhances proliferation and expression of tumorigenic cytokines in a bladder cancer cell line ［J］.Cancer Research,2012,72(8 Supplement):159.
［28］ WEISS C,WOLZE C,ENGEHAUSEN DG,et al.Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer:an alternative to intravesical therapy or early cystectomy［J］.J Clin Oncol,2006,24(15):2318-2324.
［29］ FISCHER-VALUCK BW,MICHALSKI JM,CONTRERAS JA,et al.A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs.urothelial carcinoma of the bladder using the National Cancer Database ［J］.Clin Transl Radiat Oncol,2019,15:38-41.
［30］ LERNER SP,BAJORIN DF,DINNEY CP,et al.Summary and recommendations from the national cancer institute's clinical trials planning meeting on novel therapeutics for non-muscle invasive bladder cancer ［J］.Bladder Cancer,2016,2(2):165-202.
［31］ PARDOLL DM.The blockade of immune checkpoints in cancer immunotherapy ［J］.Nat Rev Cancer,2012,12(4):252-264.
［32］ SIEFKER-RADTKE AO,APOLO AB,BIVALACQUA TJ,et al.Immunotherapy with checkpoint blockade in the treatment of urothelial carcinoma ［J］.J Urol,2018,199(5):1129-1142.
［33］ WRIGHT KM.FDA approves pembrolizumab for bcg-unresponsive NMIBC ［J］.Oncology (Williston Park),2020,34(2):44.
［34］ ALANEE S,SANA S,EL-ZAWAHRY A,et al.Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatment ［J］.World Journal of Urology,2021,39(10):3807-3813.
［35］ BALAR AV,KULKARNI GS,UCHIO EM,et al.Keynote 057:Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG) ［J］.Journal of Clinical Oncology,2019,37(7_suppl):350.
［36］ BALAR AV,KAMAT AM,KULKARNI GS,et al.Pembrolizumab (pembro) for the treatment of patients with Bacillus Calmette-Guérin (BCG) unresponsive,high-risk (HR) non-muscle-invasive bladder cancer (NMIBC):Over two years follow-up of KEYNOTE-057 ［J］.Journal of Clinical Oncology,2020,38(15_suppl):5041.
［37］ INMAN BA,HAHN NM,STRATTON K,et al.A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer ［J］.European Urology Oncology,2023,6(3):313-320.
［38］ HAHN NM,O'DONNELL MA,EFSTATHIOU JA,et al.A phase 1 trial of durvalumab in combination with Bacillus Calmette-Guerin (BCG) or external beam radiation therapy in patients with BCG-unresponsive non-muscle-invasive bladder cancer:The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study ［J］.European Urology,2023,83(6):486-494.
［39］ BABJUK M,BURGER M,COMPéRAT EM,et al.European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-2019 update ［J］.Eur Urol,2019,76(5):639-657.
［40］ HOU Z,LI Y,HUANG Y,et al.Phytosomes loaded with mitomycin C-soybean phosphatidylcholine complex developed for drug delivery ［J］.Mol Pharm,2013,10(1):90-101.
［41］ MYERS AL,ZHANG YP,KAWEDIA JD,et al.Solubilization and stability of mitomycin C solutions prepared for intravesical administration ［J］.Drugs RD,2017,17(2):297-304.
［42］ VAN VALENBERG FJP,VAN DER HEIJDEN AG,LAMMERS RJM,et al.Intravesical radiofrequency induced hyperthermia enhances mitomycin C accumulation in tumour tissue ［J］.Int J Hyperthermia,2018,34(7):988-993.
［43］ KISS B,SCHNEIDER S,THALMANN GN,et al.Is thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer［J］.Int J Urol,2015,22(2):158-162.
［44］ COENEN J,VAN VALENBERG FJP,ARENDS TJH,et al.Chemohyperthermia using MMC in non-muscle-invasive bladder cancer:Current status and future perspectives［J］.Arch Esp Urol,2018,71(4):400-408.
［45］ ALFRED WITJES J,HENDRICKSEN K,GOFRIT O,et al.Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder:experience of the European Synergo working party ［J］.World J Urol,2009,27(3):319-324.
［46］ PIGNOT G,BABOUDJIAN M,LEBACLE C,et al.Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failure ［J/OL］.World Journal of Urology,2023［2023-02-22］.https://pubmed.ncbi.nlm.nih.gov/36811732/.DOI: 10.1007/s00345-023-04332-z.
［47］ PIJPERS OM,HENDRICKSEN K,MOSTAFID H,et al.Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer ［J］.Urologic Oncology,2022,40(2):62.e13-62.e20.
［48］ KAMAT AM,COLOMBEL M,SUNDI D,et al.BCG-unresponsive non-muscle-invasive bladder cancer:recommendations from the IBCG ［J］.Nat Rev Urol,2017,14(4):244-255.
［49］ JUVET T,MARI A,LAJKOSZ K,et al.Sequential administration of Bacillus Calmette-Guerin (BCG) and electromotive drug administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure ［J］.Urol Oncol,2020,38(11):850.e9-e15.
［50］ RAILKAR R,AGARWAL PK.Photodynamic therapy in the treatment of bladder cancer:Past challenges and current innovations ［J］.Eur Urol Focus,2018,4(4):509-511.
［51］ MONRO S,COLON KL,YIN H,et al.Transition metal complexes and photodynamic therapy from a tumor-centered approach:Challenges,opportunities,and highlights from the development of TLD1433 ［J］.Chem Rev,2019,119(2):797-828.
［52］ GRIMBERG DC,SHAH A,INMAN BA.Overview of taris GemRIS,a novel drug delivery system for bladder cancer ［J］.European Urology Focus,2020,6(4):620-622.
［53］ VAN DER HEIJDEN MS,CUTIE C,HAMPRAS S,et al.SunRISe-1:Phase 2b study of TAR-200 plus cetrelimab,TAR-200 alone,or cetrelimab alone in participants with high-risk nonmuscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guérin who are ineligible for or decline radical cystectomy ［J］.Journal of Clinical Oncology,2022,40(6 Suppl):TPS593.
［54］ PACKIAM VT,LAMM DL,BAROCAS DA,et al.An open label,single-arm,phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer:Interim results ［J］.Urol Oncol,2018,36(10):440-447.
［55］ UCHIO EM,LAMM DL,SHORE ND,et al.A phase 3,single-arm study of CG0070 in subjects with nonmuscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG) ［J］.Cancer Research,82(12 Suppl):CT233.
［56］ SHORE ND,BOORJIAN SA,CANTER DJ,et al.Intravesical rAd-IFNα/Syn3 for patients with high-grade,Bacillus Calmette-Guerin-refractory or relapsed non-muscle-invasive bladder cancer:A phase II randomized study ［J］.J Clin Oncol,2017,35(30):3410-3416.
［57］ HASSLER MR,SHARIAT SF,SORIA F.Salvage therapeutic strategies for bacillus Calmette-Guerin failure ［J］.Curr Opin Urol,2019,29(3):239-246.
［58］ LEE A.Nadofaragene firadenovec:First approval ［J］.Drugs,2023,83(4):353-357.
［59］ KOWALSKI M,ENTWISTLE J,CIZEAU J,et al.A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG refractory and BCG-intolerant patients［J］.Drug Des Devel Ther,2010,4:313-320.
［60］ ZAHOOR H,MIR MC,BARATA PC,et al.Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer ［J］.Invest New Drugs,2019,37(6):1231-1238.
［61］ CHAMIE K,CHANG SS,GONZALGO M,et al.Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC)［J］.Clin Oncol,2022,40(6):4058.
［62］ WEIR SJ,WOOD R,SCHORNO K,et al.Preclinical pharmacokinetics of fosciclopirox,a novel treatment of urothelial cancers,in rats and dogs ［J］.J Pharmacol Exp Ther,2019,370(2):148-159.
［63］ COOLEY LF,MCLAUGHLIN KA,MEEKS JJ.Genomic and therapeutic landscape of non-muscle-invasive bladder cancer ［J］.Urol Clin North Am,2020,47(1):35-46.
［64］ PIETZAK EJ,BAGRODIA A,CHA EK,et al.Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets ［J］.Eur Urol,2017,72(6):952-959.
［65］ SEIDL C.Targets for therapy of bladder cancer ［J］.Semin Nucl Med,2020,50(2):162-170.

Memo

Memo:
-
Last Update: 1900-01-01